Despite promising clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from managed care entities. Such companies are typically erecting limitations to reimbursement, such as high cost requirements and approval processes that limit user access. Analyst